DiaMedica Therapeutics Inc. Common Stock (DMAC)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Viewed through a value lens, DiaMedica is a clinical-stage biotech, not an operating business with earnings. It has no revenue in filed periods, and losses have widened: in fiscal FY2023, year ended 2023-12-31, net income was -$19.4M; in fiscal FY2024, year ended 2024-12-31, -$24.4M; in fiscal FY2025, year ended 2025-12-31, -$32.8M. In fiscal Q2 2026, quarter ended 2026-06-30, net income was -$10.1M and diluted EPS -$0.19, versus -$7.7M and -$0.18 in fiscal Q2 2025, quarter ended 2025-06-30. At the 2026-10-13 close, market cap was $421.7M and price $7.82. FairStock calculations show P/E -10.86, P/B 11.01, ROE -114.61%, ROCE -64.12%, trailing FCF -$31.5M, FCF yield -7.5%, Piotroski 0/9, and FairStock Score 20/100. The Lynch category is none because it lost money in each of the last four years. Debt is zero, D/E 0.00, and Altman Z-Score 32.98, so balance-sheet solvency is not the immediate issue; cash burn is. The moat is unproven. DM199 in Phase 2/3 for acute ischemic stroke and Phase 2 for other severe ischemic conditions could create regulatory exclusivity if approved, but today there is no revenue to protect. Valuation rests almost entirely on binary clinical outcomes, not on demonstrated earning power. That is speculation, not Graham-style intrinsic value.

In plain English: DiaMedica Therapeutics is a small drug company with no product sales yet. It is testing treatments for stroke and other serious illnesses, but it has lost money for years and its losses are getting bigger. Based on the numbers given, the stock price looks expensive for a business that currently earns nothing, so its value depends mostly on whether its trials succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer